Previous Close | 39.2 |
1-Year Change | 55.68% |
6-Months Change | 81.31% |
3-Months Change | 26.21% |
Moving Avg (50d) | 34.582 |
Moving Avg (200d) | 26.247 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.86B |
Beta (3-Years) | 2.15 |
Revenue Growth (ttm) | 21.01% |
Net Profit Margin (ttm) | -14.56% |
Return On Assets (ttm) | -4.44% |
EPS (ttm) | -0.69 |
PE Ratio (ttm) | -56.81 |
Dividend Yield | % |
Asset Description: | Veracyte, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-19 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
38.416 | 37.24 | 36.456 | 35.28 | 33.32 | 31.36 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |